---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-027171"
form_type: "8-K"
ticker: "PPCB"
cik: "0001517681"
company_name: "Propanc Biopharma, Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T01:43:02.657162+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Propanc Biopharma issues $45K convertible note at 65% discount; terminates $5M equity line

## Summary
- Issued $45,000 convertible promissory note to 1800 Diagonal Lending LLC, convertible at 65% of market price after 180 days.
- 8% annual interest (22% on default), maturity July 19, 2024; prepayment allowed at premiums up to 129% within 180 days.
- Termination of $5,000,000 equity line agreement with an institutional investor on July 25, 2023 due to registration disagreement.
- Note issued as unregistered security under Section 4(a)(2) and Regulation D; proceeds for working capital.
- Company must maintain share reserve of 500% of conversion shares and avoid becoming shell company without investor consent.

## SEC filing metadata
- accession: 0001493152-23-027171
- form_type: 8-K
- ticker: PPCB
- cik: 0001517681
- company_name: Propanc Biopharma, Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 1.02, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517681/000149315223027171/0001493152-23-027171-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517681/000149315223027171/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-027171
- JSON: https://secwatch.observer/filing/0001493152-23-027171.json
- Plain text: https://secwatch.observer/filing/0001493152-23-027171.txt

## Key facts
- Debt Financings
  Propanc Biopharma, Inc. incurred convertible notes of $45,000 with an investor at 8% per annum, which may be increased to 22% in the event of a default maturing July 19, 2024.
  - Instrument: convertible notes
  - Principal: $45,000
  - Counterparty: an investor
  - Rate: 8% per annum, which may be increased to 22% in the event of a default
  - Maturity: July 19, 2024
  - Event: incurrence
  source text: On July 19, 2023, Propanc Biopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), which closed on July 28, 2023, pursuant to which the Investor purchased a convertible promissory note (the “Note”) from the Company in the aggregate principal amount of $45,000
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517681/000149315223027171/0001493152-23-027171-index.htm
- Material Agreements
  Propanc Biopharma, Inc. terminated Equity Line Agreement (effective 2023-07-25).
  - Action: termination
  - Agreement: equity purchase
  - Effective: 2023-07-25
  source text: On July 25, 2023, due to a disagreement between the parties relating to the registration of such shares of Common Stock, the Company notified such investor of the termination of the Equity Line Agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517681/000149315223027171/0001493152-23-027171-index.htm
- Material Agreements
  Propanc Biopharma, Inc. entered into Purchase Agreement valued at $45,000 (effective 2023-07-19).
  - Action: entry
  - Agreement: equity purchase
  - Value: $45,000
  - Effective: 2023-07-19
  source text: On July 19, 2023, Propanc Biopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), which closed on July 28, 2023, pursuant to which the Investor purchased a convertible promissory note (the “Note”) from the Company in the aggregate principal amount of $45,000
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517681/000149315223027171/0001493152-23-027171-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.